

Best Evidence Summaries of Topics in Mental Healthcare

BEST in MH clinical question-answering service

Question

In adults with dementia and a very low body mass index (BMI e.g. <17), how effective are cholinesterase inhibitors, compared to any other intervention, in improving patient outcomes?

Clarification of question using PICO structure

Patients: Adults with dementia and a very low body mass index (BMI e.g. <17)

Intervention: Cholinesterase inhibitors Comparator: Any other intervention Outcome: Improving patient outcomes

Plain language summary

No high quality, relevant research evidence was identified.



Email: awp.BESTinMH@nhs.net Phone: 0117 378 4232/4233/4335

Clinical and research implications

No high quality, relevant research evidence was identified.

What does the evidence say?

Number of included studies/reviews (number of participants)

N/A

Main findings

N/A

Authors conclusions

N/A

Reliability of conclusions/Strength of evidence

N/A

What do guidelines say?

NICE guidelines do not comment on the use of cholinesterase inhibitors in individuals with dementia with a very low BMI.

Date question received: 14/07/2016 Date searches conducted: 01/08/2016 Date answer completed: 30/08/2016

Search details

Source	Search Strategy	Number of hits	Relevant evidence identified
Guidelines			
NICE	Dementia	2	0
MEDLINE	(donepezil OR galantamine OR rivastigmine OR tacrine OR memantine).ti,ab	25	
	(cholinesterase ADJ inhibitor*).ti,ab		
	(exelon OR reminyl OR Aricept OR E2020).ti,ab		
	(ENA adj2 713).ti,ab		
	ENA-713.ti,ab		
	exp CHOLINESTERASE INHIBITORS/		
	1 OR 2 OR 3 OR 4 OR 5 OR 6		
	dement*.ti,ab		
	exp DEMENTIA/		
	8 OR 9		
	exp THINNESS/		
	exp BODY WEIGHT/ OR exp WEIGHT LOSS/		
	(underweight OR under-weight OR (under adj2 weight)).af		
	11 OR 12 OR 13		
	7 AND 10		
	14 AND 15		
EMBASE	(donepezil OR galantamine OR rivastigmine OR tacrine OR memantine).ti,ab	652	
	(cholinesterase ADJ inhibitor*).ti,ab		
	(exelon OR reminyl OR Aricept OR E2020).ti,ab		
	(ENA adj2 713).ti,ab		
	ENA-713.ti,ab		
	exp CHOLINESTERASE INHIBITORS/		
	17 OR 18 OR 19 OR 20 OR 21 OR 22		

	dement*.ti,ab		
	exp DEMENTIA/		
	24 OR 25		
	exp BODY WEIGHT/		
	exp WEIGHT/		
	exp UNDERWEIGHT/		
	exp BODY MASS/		
	(underweight OR under-weight OR (under adj2 weight)).af		
	27 OR 28 OR 29 OR 30 OR 31		
	23 AND 26		
	32 AND 33		
PsycINFO/CINAHL	(donepezil OR galantamine OR rivastigmine OR tacrine OR memantine).ti,ab	4	
	(cholinesterase ADJ inhibitor*).ti,ab		
	(exelon OR reminyl OR Aricept OR E2020).ti,ab		
	(ENA adj2 713).ti,ab		
	ENA-713.ti,ab		
	exp CHOLINESTERASE INHIBITORS/		
	35 OR 36 OR 37 OR 38 OR 39 OR 40		
	dement*.ti,ab		
	exp DEMENTIA/		
	42 OR 43		
	exp BODY WEIGHT/ OR exp UNDERWEIGHT/		
	(underweight OR under-weight OR (under adj2 weight)).af		
	45 OR 46		
	41 AND 44		
	47 AND 48		
CENTRAL	donepezil or galantamine or rivastigmine or tacrine or memantine	45	
	cholinesterase inhibitor		
	exelon or reminyl or Aricept or E2020		
	MeSH descriptor: [Cholinesterase Inhibitors] explode all trees		
	#1 or #2 or #3 or #4		

dementia	
MeSH descriptor: [Dementia] explode all trees	
#6 or #7	
#5 and #8	
underweight or under-weight	
under weight	
MeSH descriptor: [Thinness] explode all trees	
#10 or #11 or #12	
#9 and #13	

Disclaimer

BEST in MH answers to clinical questions are for information purposes only. BEST in MH does not make recommendations. Individual health care providers are responsible for assessing the applicability of BEST in MH answers to their clinical practice. BEST in MH is not responsible or liable for, directly or indirectly, any form of damage resulting from the use/misuse of information contained in or implied by these documents. Links to other sites are provided for information purposes only. BEST in MH cannot accept responsibility for the content of linked sites.

© Best Evidence Summaries of Topics in Mental Health 2015